Wheelock E F, Robinson M K, Truitt G A
Cancer Metastasis Rev. 1982;1(1):29-44. doi: 10.1007/BF00049479.
The L5178Y-cell tumor dormant state in DBA/2 mice is an excellent model for assessing immunologically mediated tumor-growth restraint mechanisms associated with establishment and control of a tumor dormant state. It has enabled us to relate components of the host's tumor suppressive immune system to the stage of tumor dormancy and the magnitude of the tumor burden. A strong CTL response has been associated with establishment of the tumor dormant state and can be reelicited in vivo or in vitro, after its initial decline, by reexposure to tumor antigen. This reelicitation is mediated via immunologic stimulation of memory CTL. Combined cultures of NAD T-lineage lymphocytes and macrophages from tumor dormant mice produce considerable cytolytic activity where little or no activity can be detected in the individual populations. Based on the similar pattern of tumor target cell specificity of the two responses, it is likely that memory CTL contribute to this synergistic cytolytic activity. The synergistic cytolytic response persists after CTL activity has waned to undetectable levels and is probably the predominant cytolytic activity associated with maintenance of the tumor dormant state. However, this activity may be obscured by proliferation of endogenous tumor cells, which in turn triggers direct macrophage-mediated cytolytic activity. The target cell specificity of this direct macrophage-mediated cytolytic response is also similar to the CTL response suggesting T cell (or memory CTL) involvement in its generation. The L5178Y-cell tumor dormant model is well suited for attempts at cure with immunotherapy. Active specific and nonspecific immunotherapy are each capable of eliminating all tumor cells from approximately 50% of tumor dormant mice. The L5178Y-cell tumor dormant state is one of several animal models of tumor dormancy. The great variety of growth restraint mechanisms that control tumor dormant states in animal systems is strong evidence that tumor dormant states exist in cancer in human beings.
DBA/2小鼠中的L5178Y细胞肿瘤休眠状态是评估与肿瘤休眠状态的建立和控制相关的免疫介导的肿瘤生长抑制机制的极佳模型。它使我们能够将宿主肿瘤抑制免疫系统的组成部分与肿瘤休眠阶段及肿瘤负荷大小联系起来。强烈的CTL反应与肿瘤休眠状态的建立有关,在其最初下降后,通过再次暴露于肿瘤抗原,可在体内或体外再次引发这种反应。这种再次引发是通过记忆CTL的免疫刺激介导的。来自肿瘤休眠小鼠的NAD T细胞系淋巴细胞和巨噬细胞的联合培养产生了相当大的细胞溶解活性,而在单个细胞群体中几乎检测不到或根本检测不到活性。基于两种反应相似的肿瘤靶细胞特异性模式,记忆CTL可能促成了这种协同细胞溶解活性。在CTL活性减弱到无法检测的水平后,协同细胞溶解反应仍然存在,并且可能是与维持肿瘤休眠状态相关的主要细胞溶解活性。然而,这种活性可能会被内源性肿瘤细胞的增殖所掩盖,而内源性肿瘤细胞的增殖反过来又会触发直接的巨噬细胞介导的细胞溶解活性。这种直接的巨噬细胞介导的细胞溶解反应的靶细胞特异性也与CTL反应相似,表明T细胞(或记忆CTL)参与了其产生过程。L5178Y细胞肿瘤休眠模型非常适合尝试用免疫疗法进行治疗。主动特异性和非特异性免疫疗法都能够使大约50%的肿瘤休眠小鼠体内的所有肿瘤细胞被清除。L5178Y细胞肿瘤休眠状态是几种肿瘤休眠动物模型之一。动物系统中控制肿瘤休眠状态的多种生长抑制机制有力地证明了人类癌症中存在肿瘤休眠状态。